期刊文献+

结直肠癌术后辅助化疗对血脂变化的影响 被引量:5

Serum lipid in colorectal cancer before and after chemotherapy
下载PDF
导出
摘要 目的:探讨结直肠癌患者术后辅助化疗前后血脂水平的变化及不同化疗方案对血脂变化的影响。方法:对127例结直肠癌患者术后辅助化疗前后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)水平进行测定并比较分析。结果:化疗后,TG、HDL、LDL水平较化疗前升高,差异有统计学意义(P<0.05)。TC值较化疗前增高,但差异无统计学意义(P>0.05)。含奥沙利铂的化疗方案与卡培他滨单药方案相比对TC、TG、LDL的影响更加显著,差异有统计学意义(P<0.05)。结论:结直肠癌患者在术后辅助化疗期间存在血脂代谢紊乱,以血清TG、HDL、LDL升高为特点;不同化疗方案对血脂变化的影响存在差异。 Objective: To evaluate the level of serum lipid in colorectal cancer patients before and after chemotherapy. Methods: All 127 patients diagnosed with colorectal cancer were included in our study. Blood specimens were collected before and after chemotherapy. High density lipoprotein cholesterol and low density lipoprotein cholesterol were assessed by enzymatic kits. Results: The mean triglyceride,high density lipoprotein cholesterol and low density lipoprotein cholesterol were significantly higher after chemotherapy. Whereas,the mean total cholesterol was higher after therapy; but no statistically significance. In addition,significant difference on serum lipid alterations existed between capecitabine and the regimen containing oxaliplatin. Conclusion: The lipid metabolism disorders exist during chemotherapy in patients with colorectal cancer and the effects on serum lipid with different chemotherapy regimens are significantly distinct.
出处 《现代肿瘤医学》 CAS 2016年第22期3589-3591,共3页 Journal of Modern Oncology
关键词 结直肠癌 化疗 血脂 colorectal cancer chemotherapy serum lipid
  • 相关文献

参考文献5

二级参考文献73

  • 1Jui-HaoChen,Jiann-HomgYeh,Hsin-WenLai,Chao-ShengLiao.Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis[J].World Journal of Gastroenterology,2004,10(15):2272-2274. 被引量:62
  • 2吴建新,陈源文,罗声政,胡颖,董国芳,李定国,陆汉明.急性胰腺炎合并高甘油三酯血症的发病类型和预后[J].中国实用内科杂志,2004,24(11):667-669. 被引量:62
  • 3黄维江,胡汉华.妊娠合并胰腺炎7例报告[J].中国普通外科杂志,2005,14(5):394-395. 被引量:4
  • 4王刚,孙备,姜洪池.高脂血症急性胰腺炎的研究进展[J].中国普通外科杂志,2005,14(11):857-859. 被引量:74
  • 5Cats A. New development in systemic chemotherapy in advanced colorectal cancer [J]. Seand J Gastroenterol Suppl, 2003, (239) : 78-86.
  • 6The Advanced Colorectal Cancer MetaAnalysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate [J]. J Clin Oncol, 1992,10(6) : 896-903.
  • 7Poon M A, O'Connell M J, Wieand H S, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer [J]. J Clin Oncol, 1991,9(11):1967- 1972.
  • 8de Gramont A, Bosset J F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluoronracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study [J]. J Clin Oncol, 1997,15(2): 808-815.
  • 9Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase Ⅱ studies of oxaliplatin (LOHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluorepyrimidines [J]. Ann Oncol, 1996,7( 1 ) :95-98.
  • 10Becouarn Y, Ychou M, Ducreux M, et al. Phase H trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers [J]. J Clin Oncol, 1998,16 ( 8 ) : 2739-2744.

共引文献212

同被引文献29

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部